Occurrence and Mortality of Stiff Person Syndrome in Denmark Authors: Henrik Toft Sørensen, Trine Toft Sørensen, Holly Elser, Erzsébet Horváth-Puhó Published: 2026 ABSTRACT AbstractIntroductionStiff person syndrome is a rare and progressive neurological disorder, yet evidence on long-term outcomes is limited. We examined the occurrence and mortality associated with stiff person syndrome in Denmark.MethodsWe conducted a population-based cohort study including all Danish citizens from 2001 to 2022. Individuals with a first-time diagnosis of stiff person syndrome (N = 30) were identified in the Danish National Patient Registry covering all Danish hospitals and matched 1:100 on sex and birth year with persons from the general population (N = 3,000). Incidence, prevalence, cumulative mortality, and mortality rates were estimated, and Cox proportional hazards regression was used to compute hazard ratios (HRs) as an estimate of mortality rate ratios adjusted for sex, year of birth, and comorbidity with 95% confidence intervals (CIs).ResultsThirty patients were diagnosed during the study period; 53.3% were male, and median age at diagnosis was 50 years. Incidence increased from 0.11 per 1,000,000 person-years (2001–2008) to 0.43 (2017–2022). Prevalence rose from 1.32 per 1,000,000 in 2016 to 3.94 in 2022. The 10-year cumulative mortality in the stiff person syndrome cohort was 27.5% (95% CI: 13.8–50.1) (HR = 4.1 [95% CI: 1.9–8.9).ConclusionStiff person syndrome is a rare disorder with increasing incidence and prevalence and high mortality. Introduction Stiff person syndrome was first described in 1956 as “stiff man syndrome.”[1] It is a rare progressive autoimmune neurological disorder characterized by severe muscle stiffness, painful spasms, often inability to walk, and permanent disability [2]. These symptoms can fluctuate, often worsening over time which can impair mobility and lead to disability [3]. Primary symptoms include stiffness, especially in the trunk and abdomen, and painful muscle spasms. These spasms may be triggered by sudden movements, emotional stress, or cold temperatures. Additional symptoms include an unsteady gait, double vision, or slurred speech. The main disease mechanism involves impaired GABAergic inhibition and autoimmunity, with antibodies against glutamic acid decarboxylase and other inhibitory synaptic proteins leading to reduced inhibitory signaling and subsequent motor neuron hyperexcitability that underlies stiffness and spasm [2]. Consistent with this, therapies targeting pathogenic IgG, such as efgartigimod, have recently shown promising results [4]. There is no cure and there are no approved therapies for stiff person syndrome. Treatment includes symptomatic management with benzodiazepines and immunomodulatory treatment with intravenous immunoglobulins, rituximab, or plasmapheresis. Physical therapy and lifestyle adjustments can help manage symptoms and improve quality of life [5]. As population-based data on occurrence and mortality of stiff person syndrome remain limited, we examined the incidence, prevalence, and mortality of stiff person syndrome in Denmark. Methods Setting In Denmark, access to hospital care is universal and tax supported [6–8]. The Civil Personal Registration numbers (unique identifier that encodes sex and date of birth), which has been assigned to all Danish residents since 1968 [9] are used in all Danish registries. Our source population comprises the entire Danish population from January 1, 2001, through December 31, 2022 (approximately 7.7 million people). Stiff Person Syndrome Cohort The Danish National Patient Registry (DNPR) has tracked non-psychiatric hospitalizations since 1977, and outpatient hospital clinic and emergency room visits since 1995. Diagnoses were coded according to the 8th Revision of the International Classification (ICD-8) through 1993 and the 10th Revision (ICD-10) thereafter. The DNPR contains information on the primary diagnosis (i.e., the main reason for the hospital contact) and secondary diagnoses related to the current hospital visit, for example, underlying chronic diseases, as well as surgical procedures coded according to the Nordic Medico-Statistical Committee (NOMESCO) classification system. A specific ICD-10 code for stiff person syndrome, G258D, was introduced in Denmark in 2001. We obtained information on all patients registered with this diagnostic code during the study period. General Population Comparison Cohort For each person with stiff person syndrome, up to 100 comparators were randomly sampled, with replacement, from the Danish general population using the Civil Registration System. Comparison cohort members were matched on sex and birth year and were assigned an index date corresponding to the diagnosis date of their match with stiff person syndrome. Comparison cohort members were alive at the index date and did not have a history of stiff person syndrome. Mortality We linked both cohorts to the Danish Civil Registration System to obtain complete information on all-cause mortality and dates of death, ensuring virtually complete follow-up. Comorbidities Comorbidities for the two cohorts were identified based on the diseases included in the Charlson Comorbidity Index (CCI), which includes 19 major diseases, each assigned a specific weight. Information on specific diseases was retrieved from the DNPR based on the entire hospital history [10]. Statistical Analyses We computed both the incidence and prevalence of stiff person syndrome. The incidence rates were calculated per 1,000,000 person-years. Point prevalence was calculated per 1,000,000 persons for 2016 and 2022 by dividing the number of persons with stiff person syndrome alive at mid-year by the corresponding mid-year population size. Ten-year cumulative mortality was estimated using the Kaplan-Meier method, given the absence of competing events in the overall mortality analyses. Cox proportional hazards regression was used to compute hazard ratios (HRs) with corresponding 95% confidence intervals (CIs) as an estimate of mortality rate ratio among patients with stiff person syndrome compared to the matched comparison cohort adjusted for sex, year of birth, and CCI score. The proportional hazards assumption was assessed visually using log-minus-log curves and was found to be valid. Results We identified 30 persons diagnosed with stiff person syndrome and 3,000 matched persons from the Danish general population. Approximately half of persons diagnosed with stiff person syndrome were male (53.3%) and the median age at diagnosis was 50 years (interquartile range 35–65 years). There were 8 (26.7%) deaths recorded among persons with stiff person syndrome and 301 (10.0%) among matched persons (Table 1). Table 1.Characteristics of the stiff person syndrome cohort and a comparison cohort sampled from the general population and matched on sex, year of birth, and index date, Denmark, 2001–2022​Stiff person syndrome (N = 30)General population comparison cohort (N = 3,000)Male, n (%)16 (53.3)1,600 (53.3)Median age, years (Q1–Q3)50, 35-6550, 35-65Year of diagnosis/index date, n (%) 2001–20085 (16.7)500 (16.7) 2009–201610 (33.3)1,000 (33.3) 2017–202215 (50.0)1,500 (50.0)CCI score, n (%) 014 (46.7)2,363 (78.8) 15 (16.7)331 (11.0) ≥211 (36.7)306 (10.2)Median follow-up time, years (Q1–Q3)5.0 (1.5–7.5)6.0 (3.5–10.5)Deaths during follow-up, n (%)8 (26.7%)301 (10.0) Characteristics of the stiff person syndrome cohort and a comparison cohort sampled from the general population and matched on sex, year of birth, and index date, Denmark, 2001–2022 The incidence of stiff person syndrome increased over time from 0.11 cases per 1,000,000 person-years in 2001–2008 to 0.43 cases per 1,000,000 person-years in 2017–2022 (Table 2). The prevalence of stiff person syndrome also increased over time from 1.32 cases per 1,000,000 in 2016 to 3.94 cases per 1,000,000 in 2022. Table 2.Incidence rate of stiff person syndrome, Denmark, 2001–2022 (calculated in time periods)​Number of incident casesPopulation sizea at the beginning of the yearbLength of observationIncidence rate per 1,000,000 person-years2001–200855,475,7918 years0.112009–2016105,707,2518 years0.222017–2022155,873,4206 years0.43 aSource: https://www.dst.dk/en/Statistik/emner/borgere/befolkning/befolkningstal. bUsing the last year of the analyzed period. Incidence rate of stiff person syndrome, Denmark, 2001–2022 (calculated in time periods) aSource: https://www.dst.dk/en/Statistik/emner/borgere/befolkning/befolkningstal. bUsing the last year of the analyzed period. The 2-year cumulative mortality was 17.3% (95% CI: 7.5–36.8) in the stiff person syndrome cohort versus 1.7% (95% CI: 1.3–2.3) in the comparison cohort. The 5-year cumulative mortality was 21.9% (95% CI: 10.3–42.8) versus 4.6% (95% CI: 3.9–5.5), and 10-year cumulative mortality was 27.5% (95% CI: 13.8–50.1) versus 12.6% (95% CI: 11.0–14.4), respectively (Table 3). The mortality rate was similarly elevated in the stiff person cohort (48.1 per 1,000 person-years, 95% CI: 12.5–83.7) versus comparison cohort members (11.7 per 1,000 PY, 95% CI: 10.1–13.2). After adjusting for matching variables and categorical CCI, the all-cause mortality remained elevated among persons with stiff person syndrome compared with general population comparison cohort members regardless of follow-up time (0–2 years: HR = 6.7 [95% CI: 2.6–17.5]; 0–5 years: HR = 5.0 [95% CI: 2.1–11.8]; 0–10 years HR = 4.1 [95% CI: 1.9–8.9]) (Table 3). Table 3.Mortality and unadjusted and adjusted HRs with 95% confidence intervals for the stiff person syndrome cohort and general population comparison cohort​Stiff person syndrome cohortGeneral population comparison cohortStiff person syndrome cohortGeneral population comparison cohortUnadjusted HR (95% CI)aAdjusted HR (95% CI)bfollow-up timecumulative mortality, % (95% CI)cumulative mortality, % (95% CI)mortality rate/1,000 PYs (95% CI)mortality rate/1,000 PYs (95% CI)0–2 years17.3 (7.5–36.8)1.7 (1.3–2.3)98.2 (12.1–184)8.5 (6.1–10.9)13.6 (5.3–34.6)6.7 (2.6–17.5)0–5 years21.9 (10.3–42.8)4.6 (3.9–5.5)57.4 (11.5–103)9.3 (7.6–11.1)9.0 (3.9–20.7)5.0 (2.1–11.8)0–10 years27.5 (13.8–50.1)12.6 (11.0–14.4)48.1 (12.5–83.7)11.7 (10.1–13.2)7.1 (3.1–15.3)4.1 (1.9–8.9)CI, confidence interval; PYs, person-years. aControlled for matching variables (sex, year of birth, calendar year) by study design. bControlled for matching variables by study design and adjusted for CCI score. Mortality and unadjusted and adjusted HRs with 95% confidence intervals for the stiff person syndrome cohort and general population comparison cohort CI, confidence interval; PYs, person-years. aControlled for matching variables (sex, year of birth, calendar year) by study design. bControlled for matching variables by study design and adjusted for CCI score. Discussion We examined incidence, prevalence, and mortality among persons diagnosed with stiff person syndrome in Denmark from 2001 to 2022. Although stiff person syndrome is the most common disorder associated with glutamic acid decarboxylase autoantibodies, our findings confirm that it remains a rare condition and with a substantially increased mortality. Few data exist on the occurrence of stiff person syndrome. In contrast to previous studies, our prevalence estimates are higher than those reported in a Japanese survey (0.11 per 1,000,000 individuals between 2015 and 2017) [11], but lower than estimates from a US study based on electronic health records (1.36–1.82 per 100,000 individuals between 2012 and 2022) [12]. These discrepancies likely reflect differences in study design, registry coverage, and diagnostic practices but may also relate to case definition as stiff person syndrome is increasingly understood as a group of related disorders rather than a single disease. Evidence on the long-term prognosis of stiff person syndrome is sparse and largely limited to case reports and series [13]. Scandinavian health registries provide a unique opportunity to examine long-term outcomes for rare diseases such as stiff person syndrome in a population-based framework [8]. A key finding from our analysis is the markedly increased short- and long-term mortality among patients with stiff person syndrome compared with the general population. Mortality was four- to fivefold higher than the general population, underscoring the substantial disease burden associated with stiff person syndrome. These observations highlight the need for improved therapeutic approaches that not only alleviate symptoms but also address the elevated risk of death. Achieving this will likely require treatments targeting the biological mechanisms underlying stiff person syndrome and a deeper understanding of its pathogenic pathways. Limitations This study has limitations. The DNPR was established in 1977, and the specific diagnostic code for stiff person syndrome was introduced later. Left truncation is therefore possible, although it is unlikely to meaningfully influence our findings. Use of ICD-10 codes in research carries inherent limitations, including coding errors, limited diagnostic specificity, and potential inaccuracies in the clinical diagnoses. The diagnostic ICD code for stiff person syndrome is highly specific, relies on detailed clinical evaluation, and is, therefore, expected to have high validity. The diagnosis of stiff person syndrome can be challenging in the early stages of the disease, and some cases may be misclassified or remain unrecognized. Although no studies have specifically examined diagnostic accuracy for this rare condition, the overall quality of recorded diagnoses in the Patient Registry is generally high [14]. The study period spans several years, and the increased use of imaging and other diagnostic procedures may have influenced the reported incidence. Moreover, earlier diagnosis may have prolonged the estimated survival following diagnosis. Owing to the small study population, we were unable to examine cause-specific mortality or conduct subgroup analyses. The registry data lacked detailed information on clinical characteristics, including antibody status, disease subtypes, paraneoplastic associations, and treatment exposure. These factors could, therefore, not be considered in the analysis. Conclusion In this population-based study, we found that both short- and long-term all-cause mortalities were elevated among persons diagnosed with stiff person syndrome compared with the general population cohort. Further research is needed to characterize the epidemiology and long-term prognosis of stiff person syndrome across diverse populations and to identify modifiable factors that may improve survival. Statement of Ethics The study received a required approval by the Danish Data Protection Agency (Record No. 2022-0367531/3343). There is no requirement by Danish law to obtain informed consent or an approval by an Institutional Review Board for a registry-based study. Conflict of Interest Statement Henrik Toft Sørensen reported the Department of Clinical Epidemiology, Aarhus University, receives funding for other studies in the form of institutional research grants to (and administered by) Aarhus University. The Department of Clinical Epidemiology, Aarhus University, confirms that none of these studies have any relation to the present study. Henrik Toft Sørensen has made paid evaluations for University of Oslo, the Norwegian Research Council, the Independent Research Fund Denmark, the European Research Council, and IMCOR. Funding Sources The study was conducted as a partnership between IMCOR and Aarhus University in Denmark for Sixten in the USA, which has stated that it has a contract with Kyverna. The study was conducted independently of Kyverna. Author Contributions Henrik Toft Sørensen had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Concept, design, and statistical analysis: H.T.S. and E.H.-P. Acquisition, analysis, or interpretation of data: H.T.S., T.T.S., H.E., and E.H.-P. Critical review of the manuscript for important intellectual content: all authors. Drafting of the manuscript; obtained funding; administrative, technical, or material support; and supervision: H.T.S.